While many in the biopharma world had their eyes on the European Society of Medical Oncology meeting in Copenhagen and scratched for more data – or for a sightline on the meaning of the avalanche of results that spilled out – Nicox S.A. took a back seat with its complete response letter (CRL) for the NDA related AC-170 for ocular itching in allergic conjunctivitis (AC).